Risk of QT prolongation and torsade de pointes associated with exposure to hydroxyzine: re-evaluation of an established drug.

Schlit, Anne-Françoise; Delaunois, Annie; Colomar, Aurore; Claudio, Branderley; Cariolato, Luca; Boev, Rossen; Valentin, Jean-Pierre; Peters, Christopher; Sloan, Victor S; Bentz, Jürgen W G

Schlit, Anne-Françoise; Delaunois, Annie; Colomar, Aurore; Claudio, Branderley; Cariolato, Luca; Boev, Rossen; Valentin, Jean-Pierre; Peters, Christopher; Sloan, Victor S; Bentz, Jürgen W G.

Afiliação

Schlit AF; UCB Pharma Brussels Belgium.
Delaunois A; UCB Pharma Brussels Belgium.
Colomar A; UCB Pharma Brussels Belgium.
Claudio B; Present address: Aurore Colomar, Université de Mons Mons Belgium.
Cariolato L; UBC Geneva Switzerland.
Boev R; UBC Geneva Switzerland.
Valentin JP; UCB Pharma Bulle Switzerland.
Peters C; UCB Pharma Brussels Belgium.
Sloan VS; UCB Pharma Brussels Belgium.
Bentz JWG; UCB Pharma Raleigh North Carolina USA.

Pharmacol Res Perspect ; 5(3): e00309, 2017 06.

Article em En | MEDLINE | ID: mdl-28480041

Palavras-chave

Hydroxyzine; QT prolongation; minimization; risk; torsade de pointes

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Pharmacol Res Perspect Ano de publicação: 2017 Tipo de documento: Article País de publicação: Estados Unidos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google